04:35 , Aug 1, 2019 |  BC Innovations  |  Distillery Therapeutics

Sensitizing cancer to checkpoint inhibitors by targeting the non-coding RNA LINC01139

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Blocking the long non-coding RNA LINC01139 could sensitize checkpoint inhibitor-resistant triple-negative breast cancer (TNBC) to the therapies. High LINC01139 expression levels correlated with low tumor levels of antigen-presenting cells...
00:16 , Jul 26, 2019 |  BC Innovations  |  Translation in Brief

GI infection as Parkinson’s trigger

A Canadian team has shown how bacterial GI infections can trigger Parkinson's disease in genetically susceptible individuals. The findings add to mounting evidence implicating the gut microbiome in CNS disorders including autism, Alzheimer's disease and...
05:03 , Jul 25, 2019 |  BC Innovations  |  Translation in Brief

Neoantigens in pediatric ALL could lead to cell-based therapies

Despite low tumor mutation load, strong immune responses against predicted neoantigens suggest opportunities to develop immunotherapies for pediatric acute lymphoblastic leukemia. The oncology field is increasingly turning to neoantigens -- non-self antigens arising from mutations...
00:30 , Jul 23, 2019 |  BC Extra  |  Preclinical News

Pact makes case for neoantigen-specific TCRs from patient blood

Preclinical studies from Pact Pharma and UCLA suggest neoantigen-specific T cells in patient blood will be reliable blueprints for the company's personalized, engineered cell therapies. Recruitment is ongoing for a Phase I study of Pact's...
22:59 , Jul 18, 2019 |  BC Innovations  |  Emerging Company Profile

Neoleukin emerges with a de novo approach to improving biologics

With a platform to design proteins from scratch, Neoleukin is making a new class of biologics that resemble their endogenous protein counterparts in structure, but not in sequence. The strategy gives the company a clean...
23:56 , Jul 8, 2019 |  BC Extra  |  Financial News

On heels of series C extension, RAPT Therapeutics files for IPO

Just weeks after topping off its series C round, Flexus spinout RAPT Therapeutics Inc. (South San Francisco, Calif.) has filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill...
22:00 , Jul 3, 2019 |  BC Extra  |  Preclinical News

Controlling CAR T toxicity with BMS's Sprycel

Bristol-Myers Squibb’s leukemia drug Sprycel could stop CAR T associated cytokine release syndrome at the root without the need for engineered control features like off-switches. One of the main limitations of CAR T cell therapy...
18:48 , Jun 27, 2019 |  BC Innovations  |  Distillery Therapeutics

4-1BBL fusion protein boosts T cell bispecific Abs for gastric cancer and lymphoma

DISEASE CATEGORY: Cancer INDICATION: Gastric cancer; lymphoma Tumor-targeted 4-1BBL fusion proteins could enhance the efficacy of T cell bispecific antibodies to treat gastric cancer and lymphoma. The fusion proteins consist of a trimer of the...
00:03 , May 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Cystine degradation boosts immunotherapies in melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Patient sample and mouse studies suggest promoting ferroptosis by degrading cystine could enhance the efficacy of anti-PD-1 immunotherapies in melanoma. In melanoma patients, high tumor levels of SLC7A11 and SLC3A2,...
21:32 , May 13, 2019 |  BC Extra  |  Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

With €62 million ($69.6 million) in series A cash to carry its two late-stage candidates through clinical development, Philogen will soon have to decide whether to rely on additional deals to find commercialization partners, or...